The Cambridge site of an international biotechnology company will cease manufacturing, leaving 150 people without a job.

Michelle Xia gained experience at U.S. pharmaceutical firms before launching her own biotech company back home in China. In a ...

The Food and Drug Administration granted Expanded Access Program authorization for NKGen's investigational drug application.

A Cambridge-based company developing gene therapies for rare diseases is laying off more than a third of its workforce.

The Food and Drug Administration on Monday named George Tidmarsh, a longtime biotech executive who has a background in ...

Jasper Therapeutics started the year with 64 full-time employees and a robust valuation of more than $320 million. Just seven ...

New board members bring decades of experience in company building, corporate strategy, commercialization, and business ...

Top experts from Amgen, CBIZ & Intrepid discuss 2025 trends in healthcare, biotech, and life sciences. Explore key insights ...

Partnership established to develop and scale production of ATL-105, a novel recombinant version of alpha-1 antitrypsin ...

Some of the most high-profile acquisitions in recent years have involved women-fronted biotechs. BioSpace reviews five of the ...

Illimis Therapeutics’ Series B round was led by Korean venture capital firm DSC Investment. Seoul-based Illimis Therapeutics ...

NATO Innovation Fund backs Portal Biotech in its first biotech move. What does this signal for strategic investment in healthcare innovation?